Patents Assigned to SBI PHARMACEUTICALS CO., LTD.
-
Patent number: 11849922Abstract: The invention provides medical or industrial light source devices, for example, an endoscope. A light source device includes: a light source emitting a light beam; a concentrator including a pair of Fresnel lenses with corrugated surfaces and concentrating the emitted light beam, the corrugated surfaces of the Fresnel lenses facing each other, and a light guide guiding the concentrated light beam. The corrugated surfaces of the pair of Fresnel lenses may be in contact with each other and one end of the light guide may be disposed at a focal point of the concentrated light beam.Type: GrantFiled: September 4, 2020Date of Patent: December 26, 2023Assignees: ARS Co., Ltd., SBI Pharmaceuticals Co., Ltd.Inventors: Yoshihito Tanaka, Kiyotaka Murakami
-
Publication number: 20230190085Abstract: The invention provides medical or industrial light source devices, for example, an endoscope. A light source device includes: a light source emitting a light beam; a concentrator including a pair of Fresnel lenses with corrugated surfaces and concentrating the emitted light beam, the corrugated surfaces of the Fresnel lenses facing each other, and a light guide guiding the concentrated light beam. The corrugated surfaces of the pair of Fresnel lenses may be in contact with each other and one end of the light guide may be disposed at a focal point of the concentrated light beam.Type: ApplicationFiled: September 4, 2020Publication date: June 22, 2023Applicants: ARS Co., Ltd., SBI Pharmaceuticals Co., Ltd.Inventors: Yoshihito TANAKA, Kiyotaka MURAKAMI
-
Patent number: 11633505Abstract: [Problem] To provide a nuclear magnetic resonance diagnostic agent that has a lower toxicity to organisms and reduced side effects and yet has a site specificity toward a specific cell, tissue, organ, etc. [Solution] When ALA or an ALA derivative is administered in vivo, a metabolite thereof is accumulated in a specific cell, tissue, organ, etc. Focusing on this phenomenon, a nuclear magnetic resonance analysis was performed on a site wherein the metabolite of ALA that had been administered in vivo would be possibly accumulated. As a result, it was surprisingly found that ALA and an ALA derivative are useful as a diagnostic agent whereby the aforesaid problem can be solved.Type: GrantFiled: December 9, 2013Date of Patent: April 25, 2023Assignees: National University Corporation Kumamoto University, University of Occupational and Enviromental Health, Japan, SBI Pharmaceuticals Co., Ltd.Inventors: Tetsuya Yoneda, Shigeru Nishizawa, Junkoh Yamamoto, Tohru Tanaka, Hidenori Itoh
-
Patent number: 11421204Abstract: A stem cell removing method that certainly-removes an undifferentiated stem cell is provided. For this object, a cell group including a stem cell and a somatic cell performed differentiation induction is cultivated in culture medium composition including photosensitizer. Light of a specific wavelength is irradiated with the cell group, and the stem cell is removed, selectively. The stem cell is a pluripotent stem cell or a somatic stem cell. The pluripotent stem cell includes either an ES cell (Embryonic Stem Cell) or an iPS cell (induced Pluripotent Stem Cell). Also, somatic stem cell includes any one of a germ stem cell, a productive cell, a pluripotent stem cell and a stem cell having unipotency.Type: GrantFiled: April 6, 2016Date of Patent: August 23, 2022Assignees: REPROCELL INCORPORATED, SBI PHARMACEUTICALS CO., LTD.Inventors: Shunsuke Yoshida, Mitsuru Inamura, Tohru Tanaka, Hiroyuki Ishikawa, Hidenori Ito
-
Patent number: 11266619Abstract: The object of the invention is to provide a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor. Provided is a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor comprising 5-aminolevulinic acids (ALAs) as the active ingredient.Type: GrantFiled: November 28, 2018Date of Patent: March 8, 2022Assignees: SBI Pharmaceuticals Co., Ltd., National Center for Child Health and DevelopmentInventors: Tohru Tanaka, Hidenori Ito, Ko Rii
-
Patent number: 11123320Abstract: Various side effects are reported for existing overactive bladder therapeutic drugs, and prophylactic or therapeutic agents for overactive bladder without side effects have been eagerly desired. The present invention provides a prophylactic or therapeutic agent for overactive bladder that comprises 5-aminolevulinic acids (ALAs) as the active ingredient.Type: GrantFiled: May 21, 2018Date of Patent: September 21, 2021Assignees: SBI PHARMACEUTICALS, CO., LTD., NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITYInventors: Tohru Tanaka, Kiwamu Takahashi, Keiji Inoue, Motoaki Saito, Masayuki Tsuda, Hideo Fukuhara, Takahira Kuno, Shogo Shimizu
-
Patent number: 10974062Abstract: The present invention includes: a front-side positive trace (2P) disposed on a flexible substrate (5); a positive external connection line (12P) connected to the front-side positive trace (2P) to supply electric power; and LED chips (4) provided to the flexible substrate (5) and connected to the front-side positive trace (2P), wherein an electric resistance between the positive external connection line (12P) and one of the LED chips (4) which is farthest from the positive external connection line (12P) is less than an internal resistance of the one of the LED chips (4).Type: GrantFiled: June 21, 2017Date of Patent: April 13, 2021Assignees: SHARP KABUSHIKI KAISHA, OSAKA CITY UNIVERSITY, SBI PHARMACEUTICALS CO.. LTD.Inventors: Katsuji Iguchi, Hiroya Sato, Takashi Yoshimoto, Jun Mori, Toshiyuki Ozawa, Kunio Awazu
-
Patent number: 10675242Abstract: The object of the invention is to elevate the stability of an aqueous formulation comprising ALAs and an iron compound. The present invention provides an aqueous formulation comprising ALAs and an iron compound, characterized in that it further comprises 0.2-30% by weight of salts, said salts are sodium salts or potassium salts, and the pH of said aqueous formulation is 2-8.Type: GrantFiled: August 23, 2017Date of Patent: June 9, 2020Assignee: SBI PHARMACEUTICALS, CO., LTD.Inventors: Mika Morishita, Urara Ota, Masahiro Ishizuka
-
Patent number: 10022345Abstract: The object of the present invention is to provide a hangover prophylactic and/or therapeutic agent. The present invention provides a hangover prophylactic and/or therapeutic agent comprising ALAs.Type: GrantFiled: November 30, 2015Date of Patent: July 17, 2018Assignee: SBI PHARMACEUTICALS CO., LTD.Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Satofumi Kawata
-
Publication number: 20180127726Abstract: A stem cell removing method that certainly-removes an undifferentiated stem cell is provided. For this object, a cell group including a stem cell and a somatic cell performed differentiation induction is cultivated in culture medium composition including photosensitizer. Light of a specific wavelength is irradiated with the cell group, and the stem cell is removed, selectively. The stem cell is a pluripotent stem cell or a somatic stem cell. The pluripotent stem cell includes either an ES cell (Embryonic Stem Cell) or an iPS cell (induced Pluripotent Stem Cell). Also, somatic stem cell includes any one of a germ stem cell, a productive cell, a pluripotent stem cell and a stem cell having unipotency.Type: ApplicationFiled: April 6, 2016Publication date: May 10, 2018Applicants: REPROCELL INCORPORATED, SBI PHARMACEUTICALS CO., LTD.Inventors: Shunsuke YOSHIDA, Mitsuru INAMURA, Tohru TANAKA, Hiroyuki ISHIKAWA, Hidenori ITO
-
Publication number: 20180125805Abstract: The present invention addresses the problem of providing a prophylactic/therapeutic agent which is inexpensive, has little adverse side effects and is effective against persistent virus infections. A 5-aminolevulinic acid compound represented by the following formula (I) (wherein R1 represents a hydrogen atom or an acyl group; and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group or an aralkyl group) or a salt thereof can be used as a prophylactic and/or therapeutic agent for virus infections to prevent proliferation of viruses.Type: ApplicationFiled: March 18, 2016Publication date: May 10, 2018Applicant: SBI Pharmaceuticals Co., Ltd.Inventors: Tohru TANAKA, Motowo NAKAJIMA, Takeshi HARA
-
Patent number: 9962350Abstract: It is intended to provide an in vitro culture medium that allows the in vitro culture of fertilized eggs to progress normally to the blastocyst stage without arresting the development thereof. The normal development rate of a fertilized egg is improved by using 5-aminolevulinic acids represented by the following formula (I) (wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group) or salts thereof as an agent for improving a normal development rate of a fertilized egg.Type: GrantFiled: July 10, 2015Date of Patent: May 8, 2018Assignees: SBI Pharmaceuticals Co., Ltd., Yamagata UniversityInventors: Tohru Tanaka, Motowo Nakajima, Kiwamu Takahashi, Osamu Nakajima
-
Patent number: 9937138Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: GrantFiled: March 9, 2016Date of Patent: April 10, 2018Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
-
Patent number: 9901558Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: GrantFiled: March 9, 2016Date of Patent: February 27, 2018Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
-
Patent number: 9895331Abstract: An object of the present invention is to provide a preventive and/or therapeutic agent for radiation damage that has a novel mechanism of action and can prevent and alleviate a wide range of symptoms of radiation damage for which no therapeutic measures have been available so far, and moreover, is highly safe to humans. A preventive and/or therapeutic agent for radiation damage comprising a compound represented by the following formula (I) such as 5-aminolevulinic acid (5-ALA) or a salt thereof as an active ingredient can be used to improve the survival rate, improve body weight reduction, and alleviate hematopoietic disorder: (wherein R1 represents a hydrogen atom or an acyl group; and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group).Type: GrantFiled: July 11, 2013Date of Patent: February 20, 2018Assignees: The University of Tokyo, SBI Pharmaceuticals Co., Ltd.Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Hidenori Ito, Kiwamu Takahashi, Kouji Matsushima, Satoshi Ueha, Jun Abe
-
Patent number: 9772286Abstract: It is to provide a method for detecting urothelial cancer simply and with high accuracy. It is a method for detecting urothelial cancer comprising administering 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these to a test subject, collecting urine from the test subject, and detecting the presence of fluorescence or amount of fluorescence in the collected urine.Type: GrantFiled: June 20, 2011Date of Patent: September 26, 2017Assignees: SBI Pharmaceuticals Co., Ltd., National University Corporation Kochi UniversityInventors: Keiji Inoue, Taro Shuin, Mutsuo Furihata, Yoshihiko Hirao, Tohru Tanaka
-
Patent number: 9757357Abstract: It is intended to provide a therapeutic and/or diagnostic agent that can be used in photodynamic therapy (PDT) or photodynamic diagnosis (PDD) capable of utilizing infrared-spectrum light such as near-infrared light (NIR), infrared light, or far-infrared light, which attains a deep body penetration. The present invention provides a photodynamic therapeutic or diagnostic agent or a photodynamic therapeutic or diagnostic kit for cancer or infectious disease, comprising: a particle (e.g., a lanthanide particle) that emits upconversion luminescence by infrared-spectrum light such as near-infrared light having a wavelength of 0.7 ?m to 2.5 ?m; and a photosensitizer (e.g., porphyrin) or a 5-aminolevulinic acid group.Type: GrantFiled: April 27, 2012Date of Patent: September 12, 2017Assignees: Tokyo Institute of Technology, SBI Pharmaceuticals Co., Ltd.Inventors: Hideya Yuasa, Shun-ichiro Ogura, Kiwamu Takahashi, Katushi Inoue, Tohru Tanaka
-
Patent number: 9743836Abstract: A system visually distinguishes diseased tissue from healthy tissue after a treatment is administered to a patient to provide different concentrations of a fluorescent marking substance between the diseased tissue and the healthy tissue. A light source illuminates the tissue with excitation light. A detector detects light returning from the tissue, and a controller characterizes the returning light according to a measured property indicative of the different concentrations. A light projector projects light having a predetermined cue in response to the characterization of the returning light.Type: GrantFiled: December 20, 2010Date of Patent: August 29, 2017Assignees: Terumo Kabushiki Kaisha, SBI Pharmaceuticals Co., Ltd.Inventors: Takeshi Tsubouchi, Katsushi Inoue
-
Patent number: 9730904Abstract: A pharmaceutical composition which is different from an existing therapeutic agent of an adult disease, of a biochemical reaction-inhibiting type, and which action mechanism is to improve the basal metabolism, wherein the composition has no side effects, and does not generate drug resistance against adult disease; and a method for preventing/treating an adult disease by using the same.Type: GrantFiled: May 8, 2015Date of Patent: August 15, 2017Assignee: SBI Pharmaceuticals Co., Ltd.Inventor: Tohru Tanaka
-
Patent number: 9707196Abstract: A method for treating side effects of anticancer agent includes administering to a subject in need thereof a prophylactic and/or therapeutic agent containing a therapeutically effective amount of a compound shown by the following Formula (I): R1—NHCH2COCH2CH2COOR2??(I) wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group, or a salt thereof.Type: GrantFiled: October 5, 2012Date of Patent: July 18, 2017Assignees: SBI Pharmaceuticals Co., Ltd., National University Corporation Kochi UniversityInventors: Tohru Tanaka, Kyoko Tsuchiya, Masahiro Ishizuka, Motowo Nakajima, Hitoshi Nakagawa, Taro Shuin, Keiji Inoue, Hideo Fukuhara, Masayuki Tsuda, Mutsuo Furihata